Pacira BioSciences, Inc. in the news

Pacira BioSciences shows weak financial performance with low ROE and declining earnings, contributing to negative market sentiment and a 12% share price drop.

Pacira BioSciences reported 6% revenue growth led by EXPAREL and iovera, expanded its non-opioid analgesic pipeline, but faces challenges with ZILRETTA sales and hospital adoption complexities.

Pacira BioSciences saw 6% revenue growth with improved margins and pipeline expansion but faces slower ZILRETTA sales and pricing challenges.

A law firm is investigating possible corporate misconduct by Pacira BioSciences and is seeking information from investors who bought shares before August 2023.

Pacira BioSciences faces revenue risks from generic competition to its main product Exparel, prompting a downgrade to speculative investment status.

Pacira Biosciences reported Q3 earnings with adjusted EPS of $0.70 beating estimates, revenue up 6.5%, but shares fell 15% this quarter amid mixed analyst revisions.

Pacira BioSciences reported Q3 2025 financial results with revenue growth driven by EXPAREL, advanced its non-opioid pain therapy pipeline, and raised full-year gross margin guidance.

Pacira BioSciences licensed AMT-143, a long-acting non-opioid pain treatment, from AmacaThera to expand its postsurgical pain management portfolio with Phase 2 trials planned for 2026.

A law firm is investigating possible corporate misconduct by Pacira BioSciences involving shareholders who bought stock before August 2023.

Pacira BioSciences will showcase real-world data on EXPAREL's effectiveness in reducing opioid use and improving recovery after surgery at AMCP Nexus 2025.

A law firm is investigating possible corporate misconduct by Pacira BioSciences affecting investors who bought shares before August 2023.

Pacira BioSciences stock received a 'sell' rating from Weiss Ratings amid mixed analyst opinions, modest earnings beat, insider selling, and strong institutional ownership.

Gagnon Securities increased its stake in Pacira BioSciences, which reported modestly better Q2 earnings and trades with mixed analyst ratings around $23.62.

Gagnon Advisors and other institutional investors have increased stakes in Pacira BioSciences, which reported modestly better Q2 earnings and focuses on non-opioid pain management.

Robeco cut its stake in Pacira BioSciences, which reported slightly better-than-expected Q2 earnings and has mixed analyst ratings, while the company focuses on non-opioid pain management products.

Pacira Biosciences' stock shows strong short-term gains outperforming the S&P 500 but faces longer-term performance challenges amid mixed technical signals.

Pacira BioSciences stock became oversold with an RSI of 28.8, suggesting recent heavy selling may be ending and a buying opportunity might arise.

Pacira BioSciences insiders have been selling shares over the past year with no insider buying, signaling potential caution for investors.

A law firm is investigating possible corporate misconduct by Pacira BioSciences affecting investors who bought shares before August 2023.

A law firm is investigating possible corporate misconduct by Pacira BioSciences affecting investors who bought shares before August 2023.